Skip to main content

Table 1 Demographic and clinical characteristics of patients initiated on MDR-TB treatment

From: Successful MDR-TB treatment regimens including Amikacin are associated with high rates of hearing loss

  Hearing loss by type of diagnosis
Variables All patients n = 437 n (%) No hearing loss n = 167 (38.2%) n (%) Hearing loss confirmed by audiogram n = 147 (33.6%) n (%) Clinical diagnosis of hearing loss n = 123 (28.2%) n (%)
Sex Female 197 (45.1) 71 (42.5) 63 (42.9) 63 (51.2)
Male 240 (54.9) 96 (57.5) 84 (57.1) 60 (48.8)
Age category in years 15 – 19 28 (6.4) 19 (11.4) 6 (4.1) 3 (2.4)
20 – 29 85 (19.5) 41 (24.6) 19 (12.9) 25 (20.3)
30 – 39 127 (29.0) 40 (24.0) 47 (32.0) 40 (32.5)
40 – 49 100 (22.9) 29 (17.4) 44 (29.9) 27 (22.0)
50 – 59 65 (14.9) 25 (15.0) 23 (15.7) 17 (13.8)
≥ 60 32 (7.3) 13 (7.8) 8 (5.4) 11 (8.9)
MDR-TB clinic Clinic 1 101(23.0) 36 (21.6) 27 (18.4) 38 (30.9)
Clinic 2 218 (50.0) 82 (49.1) 78 (53.1) 58 (47.1)
Clinic 3 35(8.0) 9 (5.4) 14 (9.2) 12 (9.8)
Clinic 4 40(9.2) 17 (10.2) 10 (6.8) 13 (10.6)
Clinic 5 43(9.8) 23 (13.8) 18 (12.2) 2 (1.6)
History of prior TB treatment Never treated for TB before 27 (6.2) 13 (7.8) 8 (5.4) 6 (4.9)
New TB regimen 142 (32.5) 59 (35.3) 38 (25.9) 45 (36.6)
Retreatment regimen 256 (58.6) 95 (56.9) 94 (64.0) 67 (54.5)
*Treated for MDR-TB 12 (2.7) 0 (0.0) 7 (4.8) 5 (4.1)
Outcome Completed 97 (22.2) 24 (14.4) 48 (32.7) 25 (20.3)
Cured 131 (30.0) 36 (21.6) 69 (46.9) 26 (21.1)
Death 53 (12.1) 29 (17.4) 10 (6.8) 14 (11.4)
Lost to follow up 10 (2.3) 4 (2.4) 3 (2.1) 5 (4.1)
Failure 22 (5) 7 (4.3) 5 (3.4) 8 (6.5)
On treatment 124 (28.4) 67 (40.1) 12 (8.2) 45 (36.6)
HIV HIV-uninfected 149 (34.1) 64 (38.3) 42 (28.6) 43 (35.0)
HIV-infected 288 (65.9) 103 (61.7) 105 (71.4) 80 (65.0)
On anti-retroviral therapy No 19 (7.0) 10 (9.7) 4 (3.8) 5 (6.2)
Yes 267 (93.0) 93 (90.3) 101 (96.2) 73 (93.8)
CD + T 4 cell count cells/milliliter (mL) category < 50 cells/mL 44 (17.0) 16 (15.6) 16 (15.2) 12 (15.0)
50 – 199 cells/mL 52 (20.2) 17 (16.5) 21 (20.0) 14 (17.5)
200 – 350 cells/mL 96 (37.2) 32 (31.0) 38 (36.2) 26 (32.5)
> 350 cells/mL 66 (25.6) 38 (36.9) 30 (28.6) 28 (35.0)
  1. *Previous history of MDR-TB treatment before enrolment in the study.